vs
弗雷斯特研究公司（FORR）与Health Catalyst, Inc.（HCAT）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是Health Catalyst, Inc.的1.4倍（$101.1M vs $74.7M），弗雷斯特研究公司净利率更高（-33.5% vs -121.9%，领先88.4%），Health Catalyst, Inc.同比增速更快（-6.2% vs -6.5%），Health Catalyst, Inc.自由现金流更多（$9.6M vs $-4.3M），过去两年弗雷斯特研究公司的营收复合增速更高（0.5% vs -0.0%）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse，原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征（LEMS）的治疗，2018年11月又获批可用于6岁及以上儿童LEMS患者。
FORR vs HCAT — 直观对比
营收规模更大
FORR
是对方的1.4倍
$74.7M
营收增速更快
HCAT
高出0.3%
-6.5%
净利率更高
FORR
高出88.4%
-121.9%
自由现金流更多
HCAT
多$13.9M
$-4.3M
两年增速更快
FORR
近两年复合增速
-0.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $74.7M |
| 净利润 | $-33.9M | $-91.0M |
| 毛利率 | 56.7% | — |
| 营业利润率 | -36.6% | -115.3% |
| 净利率 | -33.5% | -121.9% |
| 营收同比 | -6.5% | -6.2% |
| 净利润同比 | -7941.4% | -340.3% |
| 每股收益（稀释后） | $-1.75 | $-1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRHCAT
| Q4 25 | $101.1M | $74.7M | ||
| Q3 25 | $94.3M | $76.3M | ||
| Q2 25 | $111.7M | $80.7M | ||
| Q1 25 | $89.9M | $79.4M | ||
| Q4 24 | $108.0M | $79.6M | ||
| Q3 24 | $102.5M | $76.4M | ||
| Q2 24 | $121.8M | $75.9M | ||
| Q1 24 | $100.1M | $74.7M |
净利润FORRHCAT
| Q4 25 | $-33.9M | $-91.0M | ||
| Q3 25 | $-2.1M | $-22.2M | ||
| Q2 25 | $3.9M | $-41.0M | ||
| Q1 25 | $-87.3M | $-23.7M | ||
| Q4 24 | $432.0K | $-20.7M | ||
| Q3 24 | $-5.8M | $-14.7M | ||
| Q2 24 | $6.3M | $-13.5M | ||
| Q1 24 | $-6.7M | $-20.6M |
毛利率FORRHCAT
| Q4 25 | 56.7% | — | ||
| Q3 25 | 60.0% | 52.6% | ||
| Q2 25 | 55.5% | — | ||
| Q1 25 | 55.9% | — | ||
| Q4 24 | 58.8% | — | ||
| Q3 24 | 60.5% | 47.5% | ||
| Q2 24 | 57.3% | — | ||
| Q1 24 | 54.9% | — |
营业利润率FORRHCAT
| Q4 25 | -36.6% | -115.3% | ||
| Q3 25 | 4.7% | -22.9% | ||
| Q2 25 | 6.2% | -46.0% | ||
| Q1 25 | -97.5% | -25.4% | ||
| Q4 24 | -0.5% | -22.0% | ||
| Q3 24 | -0.7% | -17.9% | ||
| Q2 24 | 9.3% | -20.8% | ||
| Q1 24 | -9.3% | -30.5% |
净利率FORRHCAT
| Q4 25 | -33.5% | -121.9% | ||
| Q3 25 | -2.3% | -29.1% | ||
| Q2 25 | 3.5% | -50.8% | ||
| Q1 25 | -97.1% | -29.9% | ||
| Q4 24 | 0.4% | -26.0% | ||
| Q3 24 | -5.7% | -19.3% | ||
| Q2 24 | 5.2% | -17.8% | ||
| Q1 24 | -6.7% | -27.6% |
每股收益（稀释后）FORRHCAT
| Q4 25 | $-1.75 | $-1.29 | ||
| Q3 25 | $-0.11 | $-0.32 | ||
| Q2 25 | $0.20 | $-0.59 | ||
| Q1 25 | $-4.62 | $-0.35 | ||
| Q4 24 | $0.02 | $-0.33 | ||
| Q3 24 | $-0.30 | $-0.24 | ||
| Q2 24 | $0.33 | $-0.23 | ||
| Q1 24 | $-0.35 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $95.7M |
| 总债务越低越好 | — | $153.3M |
| 股东权益账面价值 | $126.5M | $245.8M |
| 总资产 | $404.0M | $502.6M |
| 负债/权益比越低杠杆越低 | — | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资FORRHCAT
| Q4 25 | $63.3M | $95.7M | ||
| Q3 25 | $65.1M | $91.5M | ||
| Q2 25 | $67.8M | $97.3M | ||
| Q1 25 | $75.6M | $342.0M | ||
| Q4 24 | $56.1M | $392.0M | ||
| Q3 24 | $62.8M | $387.3M | ||
| Q2 24 | $58.9M | $308.3M | ||
| Q1 24 | $61.4M | $327.8M |
总债务FORRHCAT
| Q4 25 | — | $153.3M | ||
| Q3 25 | — | $153.1M | ||
| Q2 25 | — | $153.0M | ||
| Q1 25 | — | $382.9M | ||
| Q4 24 | — | $382.4M | ||
| Q3 24 | — | $345.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FORRHCAT
| Q4 25 | $126.5M | $245.8M | ||
| Q3 25 | $157.7M | $331.9M | ||
| Q2 25 | $159.5M | $347.5M | ||
| Q1 25 | $147.4M | $376.8M | ||
| Q4 24 | $229.5M | $365.2M | ||
| Q3 24 | $234.3M | $355.0M | ||
| Q2 24 | $237.1M | $357.0M | ||
| Q1 24 | $230.9M | $357.2M |
总资产FORRHCAT
| Q4 25 | $404.0M | $502.6M | ||
| Q3 25 | $414.2M | $587.1M | ||
| Q2 25 | $436.0M | $616.2M | ||
| Q1 25 | $439.8M | $891.5M | ||
| Q4 24 | $503.9M | $858.9M | ||
| Q3 24 | $505.3M | $813.0M | ||
| Q2 24 | $524.2M | $691.7M | ||
| Q1 24 | $555.7M | $695.1M |
负债/权益比FORRHCAT
| Q4 25 | — | 0.62× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 1.05× | ||
| Q3 24 | — | 0.97× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $9.6M |
| 自由现金流率自由现金流/营收 | -4.2% | 12.9% |
| 资本支出强度资本支出/营收 | 1.1% | 0.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $18.1M | $-697.0K |
8季度趋势，按日历期对齐
经营现金流FORRHCAT
| Q4 25 | $-3.2M | $9.9M | ||
| Q3 25 | $1.2M | $-464.0K | ||
| Q2 25 | $-3.6M | $-9.0M | ||
| Q1 25 | $26.7M | $280.0K | ||
| Q4 24 | $-1.8M | $-3.5M | ||
| Q3 24 | $264.0K | $6.2M | ||
| Q2 24 | $-2.9M | $1.6M | ||
| Q1 24 | $611.0K | $10.3M |
自由现金流FORRHCAT
| Q4 25 | $-4.3M | $9.6M | ||
| Q3 25 | $524.0K | $-719.0K | ||
| Q2 25 | $-4.2M | $-9.2M | ||
| Q1 25 | $26.1M | $-390.0K | ||
| Q4 24 | $-2.5M | $-3.9M | ||
| Q3 24 | $-223.0K | $5.5M | ||
| Q2 24 | $-3.7M | $1.3M | ||
| Q1 24 | $-815.0K | $10.1M |
自由现金流率FORRHCAT
| Q4 25 | -4.2% | 12.9% | ||
| Q3 25 | 0.6% | -0.9% | ||
| Q2 25 | -3.8% | -11.4% | ||
| Q1 25 | 29.0% | -0.5% | ||
| Q4 24 | -2.3% | -4.9% | ||
| Q3 24 | -0.2% | 7.2% | ||
| Q2 24 | -3.1% | 1.7% | ||
| Q1 24 | -0.8% | 13.5% |
资本支出强度FORRHCAT
| Q4 25 | 1.1% | 0.4% | ||
| Q3 25 | 0.7% | 0.3% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.7% | 0.8% | ||
| Q4 24 | 0.6% | 0.5% | ||
| Q3 24 | 0.5% | 0.9% | ||
| Q2 24 | 0.7% | 0.4% | ||
| Q1 24 | 1.4% | 0.3% |
现金转化率FORRHCAT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.93× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |
